MapLight Therapeutics registers 13.2 million shares for resale after $150 million private placement

MapLight Therapeutics filed a Form S-1 with the SEC on September 9, 2026, registering the resale of up to 13,181,055 shares of common stock, consisting of 9,197,887 shares of common stock and 3,983,168 shares of common stock issuable upon exercise of outstanding pre-funded warrants, held by selling stockholders who received the securities in a private placement that closed on August 14, 2026¹. The company said it will not receive any proceeds from the resale of the shares by the selling stockholders¹.

The private placement itself was priced at $11.38 per share, with pre-funded warrants priced at that amount minus $0.0001 per warrant share, generating gross proceeds of approximately $150.0 million before fees and expenses¹.

MapLight describes itself as a clinical-stage biopharmaceutical company focused on central nervous system disorders¹. Its lead candidate, ML-007C-MA, is described in the filing as a combination therapy pairing a muscarinic agonist that acts on M1 and M4 receptors with a separate compound designed to counteract peripheral side effects, initially aimed at schizophrenia and Alzheimer's disease psychosis¹. The company said in July 2026 it announced positive topline results from ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for schizophrenia¹, and plans to seek an end-of-Phase 2 meeting with the FDA to discuss a Phase 3 trial design that, together with ZEPHYR, could support an initial NDA submission¹.

A second program, ML-004, is a 5-HT1B/1D agonist being developed for social communication deficit and irritability in autism spectrum disorder¹, with topline Phase 2 results from the IRIS trial announced in June 2026¹.

On the trading side, MapLight's common stock is listed on Nasdaq under the symbol MPLT, and the last reported sale price on September 8, 2026 was $13.95 per share¹.